

NSC-687852 (b-AP15)**3,5-bis[(4-nitrophenyl)methylidene]-1-prop-2-enoylpiperidin-4-one**

Cat. # SI9669


Background: Blocks 26S proteasome activity by inhibiting the ubiquitin C-terminal hydrolase 5 (UCHL5) and ubiquitin-specific peptidase 14 (USP14) activities of the 19S regulatory subunit without affecting the catalytic activity of the 20S core subunit. b-AP15 displays several differences to bortezomib including insensitivity to over-expression of the anti-apoptotic mediator Bcl-2 and anti-tumor activity in four solid tumor models.

Applications:

1. Validation studies of the deubiquitinating activities of the 19S regulatory particle as a drug target
2. Cell-based and in vitro characterization UCH-L5 or USP14 activity
3. Inhibition of the 26S proteasome through a mechanism distinct from inhibition of 20S catalytic activity

Product Information:

CAS No.	Not found
Purity:	>98% (HPLC); NMR (Conforms)
Molecular Weight:	419.4
Physical State:	Pale Yellow Powder
Quantity:	5 mg, 25 mg
Solubility:	May be dissolved in DMSO (35 mg/ml)
Storage:	Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 3 months.

**Formula:** C₂₂H₁₇N₃O₆**References**

1. D'Arcy P. *et al.* Inhibition of proteasome deubiquitinating activity as a new cancer therapy. *Nature Medicine* 2011 17:1636
2. D'Arcy P. and Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. *Int. J. Biochem. Cell Biol.* 2012 E Published ahead of print.

All products are for research use only • Not intended for human or animal diagnostic or therapeutic uses
Copyright © 2011 LifeSensors, Inc. All Rights Reserved